Abstract: | Objective To investigate the effect of Dapagliflozin in the treatment of early diabetic nephropathy and its effect on serum MCP-1 and IL-6. Methods 78 cases of patients with early diabetic nephropathy treated in our hospital from January 2019 to January 2020 were randomly divided into observation group and control group, with 39 cases in each group. Both groups received irbesartan and other conventional treatment. In addition, patients in the control group were treated with metformin, and patients in the observation group were treated with dagaglidine for 12 weeks. The changes of serum creatinine, fasting blood glucose (FBG), 2 h postprandial blood glucose (2 h PG), glycosylated hemoglobin (HbA1c), urinary albumin excretion rate (UAER) and serum McP-1 and IL-6 levels in 2 groups were compared before and after treatment. Results After treatment, FBG, 2hPG and HbA1c in the two groups were significantly decreased, and the observation group was significantly lower than the control group (P < 0.05). After treatment, UAER in both groups was significantly lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant (P < 0.05). There was no significant change in serum creatinine level in 2 groups before and after treatment (P > 0.05). After treatment, the serum LEVELS of McP-1 and IL-6 in 2 groups were significantly decreased compared with before treatment, and the observation group was significantly lower than the control group, the difference was statistically significant (P < 0.05). Pearson correlation analysis showed that UAER was positively correlated with serum MCP-1 and IL-6 in early diabetic nephropathy patients (P < 0.05). Conclusion The application of Dapagliflozin in the treatment of early diabetic kidney disease can not only effectively control the blood glucose, but also reduce the serum MCP-1 and IL-6, reduce the leakage of urine protein, and then protect the renal function. |